CND Life Sciences secured growth funding to expand the Syn-One Test, a laboratory assay that detects pathological phosphorylated alpha-synuclein to support diagnosis of Parkinson's and other neurodegenerative conditions. The test has been deployed across more than 60,000 patient evaluations since 2020, with plans to integrate it into a broader multimodal biomarker platform for earlier disease detection and characterization.
Key Points
- Syn-One Test detects abnormal phosphorylated alpha-synuclein in patient samples
- Over 60,000 patients evaluated using the assay since 2020
- Funding supports multimodal biomarker integration for early disease detection
Longevity Analysis
The ability to detect pathological alpha-synuclein in peripheral samples represents a shift in how neurodegenerative disease is identified—moving from symptomatic recognition toward asymptomatic detection in at-risk populations. Earlier identification of pathological markers creates a clinical window for intervention before neurological dysfunction becomes irreversible. Integration with additional biomarkers to characterize disease stage and progression trajectory has direct implications for both clinical trial enrollment and personalized treatment selection, where timing of therapeutic introduction correlates with outcomes. This advances the capacity to decode what is happening in the nervous system before conscious symptoms emerge.
Original published by LT Wire.